The test shall be designed to offer 45-minute identification of Flu A infection.

Currently, laboratories don’t have a rapid test to discriminate among the multiple influenza strains likely to be there this flu period – – each which have different antiviral medication susceptibilities, stated David Persing, MD, PhD, Cepheid’s Executive Vice President, Chief Medical & Technology Officer. To create this test available as quickly as possible, we intend to accelerate development by leveraging the task completed on a previous influenza project supported through a 2007 contract with the Section of Health and Human Solutions and Centers for Disease Control and Prevention .Today announced the completion of most one-year follow-up appointments for patients signed up for its two multi-center Stage III research evaluating the protection and efficacy of corneal collagen cross-linking for the treating progressive keratoconus and ectasia pursuing refractive surgery. Keratoconus can be a degenerative disease of the attention and may be the leading reason behind corneal transplants in america today.